Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants
maternal RSVpreF vaccination was associated with 78% to 81% reduction in RSV-associated hospitalization from birth through 6 months of age, with the highest vaccine effectiveness in earliest age intervals.
Commission signs joint procurement contract for up to 24 million doses of RSV vaccine ahead of the 2026-2027 winter season
The European Commission has signed a joint procurement framework contract with Moderna to access up to 24 million doses of the mRNA-based RSV (Respiratory Syncytial Virus) vaccine mRESVIA®.
Eight vaccines linked to a lower risk of dementia
A growing body of research is beginning to reveal the impact that regular routine vaccines could be having on the likelihood of conditions like dementia.
Manual for respiratory virus vaccination coverage: monitoring and reporting seasonal influenza, COVID-19, and respiratory syncytial virus immunization
This manual provides guidance for countries on monitoring and reporting vaccination coverage for seasonal influenza, COVID-19 and respiratory syncytial virus (RSV) immunization programmes.
Summary Report: IDC Stakeholder Community Meeting - 10 June 2026, Brussels
Key takeaways and next steps from the first in-person meeting of the IDC
ESWI Activity Report for 2025
Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity
These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.
News
Policy & Recommendations
Europe strengthens lab defences against key pathogens
ESWI Chair Colin Russell was featured in a Medscape article on the EU reference laboratories aiming to improve disease surveillance data, including respiratory viruses.
